-
1 Comment
Haemonetics Corporation is currently in a long term downtrend where the price is trading 36.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.
Haemonetics Corporation's total revenue sank by 7.2% to $240M since the same quarter in the previous year.
Its net income has increased by 6.6% to $32M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.4% to $57M since the same quarter in the previous year.
Based on the above factors, Haemonetics Corporation gets an overall score of 2/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
Sector | Healthcare |
Industry | Medical Devices |
ISIN | US4050241003 |
Market Cap | 3B |
---|---|
PE Ratio | 20.86 |
Target Price | 79.25 |
Beta | 0.37 |
Dividend Yield | None |
Haemonetics Corporation, a medical technology company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tool. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HAZ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025